Potential Role of Magrolimab in the Treatment of Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Eytan M. Stein, MD, provides an overview of myelodysplastic syndrome, including risk factors, symptoms, and diagnosis.

Hetty Carraway, MD, describes how MDS differs from acute myeloid leukemia (AML), and the percentage of patients who progress to AML from MDS.

Dr Eytan M Stein breaks down how patients with MDS are risk-stratified, and how the clinical outcomes differ between risk groups.

Experts explain the treatment goals for patients with MDS, and discusses the role of molecular testing in patients with MDS.

Dr Hetty Carraway reviews the available treatment options for patients with higher-risk MDS, and the biggest challenges of treatment.

Eytan M. Stein, MD, outlines the biggest factors to consider when choosing a treatment for higher-risk MDS, including the differences in quality-of-life for patients.

Hetty Carraway, MD, illustrates the role of allogenic stem cell transplant in MDS and the criteria used to determine a patient’s eligibility.

Key opinion leaders describe the role of hypomethylating agents in treating higher-risk MDS and the treatment options after HMA failure.

Drs Stein and Carraway explain the rationale for a magrolimab and azacitidine combination treatment for patients with higher-risk MDS with supporting data from 2 clinical trials.

Dr Hetty Carraway muses on whether magrolimab plus azacitadine will be used as a standard treatment for higher-risk MDS in the future.

Eytan M. Stein, MD, discusses how to treat patients with MDS who have IDH or TP53 mutations, and whether there is a role for targeted therapy in this patient population.

Dr Carraway highlights some of the most urgent unmet needs for patients with higher-risk MDS.

Dr Stein explains clinical trial data on the use of magrolimab plus azacitidine for patients with TP53-mutated AML.

Closing out their discussion, Drs Hetty Carraway and Eytan M. Stein highlight an ongoing clinical trial investigating a triplet therapy for AML.